Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONVAX-01 + anti-PD-1 + chemotherapy
- Development stage
- Unknown
- Lead developer
- Sichuan University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
ONVAX-01 + anti-PD-1 + chemotherapy is a combination immunotherapy regimen being investigated for the treatment of advanced pancreatic adenocarcinoma. The regimen consists of **ONVAX-01**, a peptide-based nanovaccine designed to stimulate a tumor-specific T-cell response; an **anti-PD-1 antibody**, which blocks the programmed cell death protein 1 (PD-1) checkpoint to enhance T-cell activity; and **standard chemotherapy**, which serves to both directly kill tumor cells and potentially prime the tumor microenvironment for immunotherapy. This triple combination aims to overcome the immunosuppressive nature of pancreatic cancer by combining active immunization, checkpoint blockade, and cytotoxic therapy.
- Other names
- ONVAX-01 combination therapyONVAX01 combination therapyONVAX 01 combination therapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)γδ TCR (T-cell receptor)Major histocompatibility complex peptide-binding groove
Beyond the preview
Go deeper on ONVAX-01 + anti-PD-1 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONVAX-01 + anti-PD-1 + chemotherapy.